U.S. License Holder:
BioMarin Pharm.
Date of License:
April-27-2017
Last Update:
Nov-30-2023
FDA-Approved Indications
BRINEURA (cerliponase alfa) is a hydrolytic lysosomal N-terminal tripeptidyl peptidase indicated to slow the loss of ambulation in symptomatic pediatric patients 3 years of age and older with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), also known as tripeptidyl peptidase 1 (TPP1) deficiency.